MDSpire - MDSpire Home

Conexiant

  • July 27, 2026
FDA Approves Centanafadine for ADHD
  • Kathryn Wighton
  • July 27, 2026
  • 3 min
  1. The FDA has approved centanafadine (SIMTRIYO) for treating ADHD in patients aged 6 years and older.
  2. Centanafadine's approval is based on four phase 3 randomized, double-blind, placebo-controlled trials.
  3. Statistically significant improvements in ADHD symptoms were observed in both adult and pediatric studies.
  4. Common adverse reactions included rash, decreased appetite, and headache, varying by age group.
  5. ADHD affects approximately 7 million pediatric patients and 15.5 million adults in the US.
...more

The Medicine Maker

  • July 27, 2026
This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer
  • July 27, 2026
  • 5 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Medicine Maker

  • July 27, 2026
The Confidentiality Barrier to AI-Enabled Drug Development
  • Timothy Pas
  • Laure Descamps
  • July 27, 2026
  • 4 min
  1. AI is transforming drug development by improving predictions of solubility and bioavailability, addressing challenges from molecular complexity.
  2. Confidentiality requirements hinder the use of client-owned molecular data in AI platforms, limiting CDMO capabilities.
  3. Developing in-house AI systems poses challenges related to data ownership and the need for client authorization for model training.
  4. AI outputs should be seen as hypothesis-generating, requiring laboratory validation due to the complexity of solubility and bioavailability.
  5. AI is expected to enhance drug development efficiency, but empirical testing will remain essential to confirm predictions.
...more

The Ophthalmologist

  • July 27, 2026
Balance Ophthalmics Appoints New CCO
  • July 27, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Ophthalmologist

  • July 27, 2026
Who Owns the Outcome?
  • Mfazo Hove
  • July 27, 2026
  • 12 min
  1. Patients paying for private eye surgery expect comprehensive care, including management of complications, but this expectation may not be met.
  2. In the UK, private ophthalmology often involves three separate entities: the surgeon, the hospital, and the provider, each with distinct responsibilities.
  3. A dropped nucleus during surgery illustrates the accountability gap, as patients may find themselves navigating different systems for complication management.
  4. Consent forms signed by patients do not typically clarify post-complication management responsibilities or coverage, leading to confusion.
  5. The fragmentation of care in private ophthalmology raises significant questions about ownership of outcomes and continuity of care.
...more

The Analytical Scientist

  • July 27, 2026
Scaling Genomics for Precision Medicine
  • July 27, 2026
  • 5 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Pathologist

  • July 27, 2026
England Expands Newborn SMA Screening
  • July 27, 2026
  • 3 min
  1. England will expand newborn genetic screening for spinal muscular atrophy (SMA) through the national heel-prick screening program.
  2. The initiative aims to identify affected infants before symptoms develop, enhancing treatment effectiveness.
  3. Laboratory testing for SMA screening is expected to begin in October 2026, three months earlier than initially planned.
  4. The program will generate real-world evidence through a £4.1 million evaluation funded by the National Institute for Health and Care Research.
  5. Implementation will continue through 2027, ensuring all newborn screening laboratories in England offer the SMA test.
...more

The Pathologist

  • July 27, 2026
Find Your Balance, Become a Better Pathologist
  • July 27, 2026
  • 10 min
  1. The author initially pursued dermatology but found a passion for pathology through a transitional residency and mentorship.
  2. The author emphasizes the need for balanced training in pathology, addressing concerns about excessive time spent in the gross room.
  3. Social media played a crucial role in the author's education and engagement with the pathology community prior to residency.
  4. An impactful moment for the author involved sharing research on NTRK-rearranged neoplasms, which resonated with patients and families.
  5. The author's experience in forensic pathology deepened their appreciation for the specialty and its broader societal implications.
...more

Clinical Research In Cardiology

  • July 27, 2026
Correction Notice: Evaluation of the Next-Generation Elecsys Troponin T High-Sensitivity Gen 6 Assay in Acute Coronary Syndrome (PERFORM-TSIX): Study Framework
  • Lori B. Daniels
  • Evangelos Giannitsis
  • Christian Mueller
  • Steven J. R. Meex
  • David Buehlmann
  • Dunja Kurtoic
  • Garnet Bendig
  • Mette Cole
  • Richard Body
  • Robert H. Christenson
  • Christa Cobbaert
  • Christopher R. deFilippi
  • Kai M. Eggers
  • Kenji Inoue
  • Allan S. Jaffe
  • Cian P. McCarthy
  • James McCord
  • Johannes T. Neumann
  • Torbjørn Omland
  • Cynthia Papendick
  • Yader Sandoval
  • Jack Wei Chieh Tan
  • Martin P. Than
  • Raphael Twerenbold
  • Nicholas L. Mills
  • W. Frank Peacock
  • July 27, 2026
  1. The article is a correction notice regarding the contributors' list for the study on the Elecsys Troponin T High-Sensitivity Gen 6 Assay.
  2. The contributors' list was initially published only in the Electronic Supplementary Material.
  3. The issue of the missing contributors' list has been rectified in the XML version of the article.
  4. The correction notice was published in the journal Clinical Research in Cardiology.
  5. The DOI for the original article is 10.1007/s00392-025-02842-x.
...more

Conexiant

  • July 24, 2026
FDA Approves Acetaminophen/Naproxen Sodium
  • Kathryn Wighton
  • July 24, 2026
  • 2 min
  1. The FDA has approved Tylenol with Naproxen, a fixed-dose combination of acetaminophen and naproxen sodium for over-the-counter use.
  2. The product is indicated for temporary relief of minor aches and pains in adults and pediatric patients aged 12 years and older.
  3. Tylenol with Naproxen is dosed every 12 hours and provides up to 12 hours of pain relief.
  4. The labeling includes warnings about liver damage, stomach bleeding, and increased risk for heart-related issues.
  5. Pregnant or breastfeeding patients are advised to consult a healthcare professional before using the product.
...more

Conexiant

  • July 24, 2026
FDA Approves Furoscix ReadyFlow
  • Kathryn Wighton
  • July 24, 2026
  • 3 min
  1. Furoscix ReadyFlow received FDA approval for treating edema in adults with heart failure or chronic kidney disease.
  2. The product delivers furosemide via a subcutaneous autoinjector, completing administration in 10 seconds or less.
  3. Clinical data showed that Furoscix ReadyFlow met its primary pharmacokinetic endpoint, providing IV-equivalent furosemide exposure.
  4. The safety profile of Furoscix ReadyFlow aligns with known effects of oral and intravenous furosemide.
  5. Common adverse events include administration-site reactions such as bruising, erythema, swelling, and pain.
...more

Conexiant

  • July 24, 2026
Addressing Gaps in HCV Treatment Data
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 24, 2026
Can Risk Infographic Encourage Smoking Cessation in Patients With COPD?
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Conexiant

  • July 24, 2026
May Kaplan Fiber Injury Signal Greater Knee Instability?
  • Andrea Surnit
  • July 24, 2026
  • 3 min
  1. Kaplan fiber injury was found to be independently associated with greater anterior tibial subluxation in patients with ACL injury.
  2. The study evaluated 132 patients aged 14 to 55 who underwent primary ACL reconstruction and had MRI within 12 weeks of injury.
  3. KF injury was present in 36% of patients and was associated with a higher frequency of concomitant anterolateral ligament injury.
  4. Multivariable analysis showed that KF injury increased anterior tibial subluxation by an average of 3.4 mm.
  5. The study highlights the need for larger, multicenter studies to validate the findings and assess clinical applicability.
...more

Conexiant

  • July 24, 2026
0.3% HA Eye Drops May Improve Dry Eye
  • Andrea Surnit
  • July 24, 2026
  • 3 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

Conexiant

  • July 24, 2026
Plant-Based Diets Linked to Fewer Recurrent UTIs
  • Meg Barbor
  • July 24, 2026
  • 6 min

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Conexiant

  • July 24, 2026
Cannabinoids Fall Short Across Most Psychiatric Disorders
  • Kathryn Wighton
  • July 24, 2026
  • 4 min

Share your perspective with a quick, clinically relevant poll that captures real-world insights and clinician sentiment.

Take the Poll

The Medicine Maker

  • July 24, 2026
Biopharma Vital Signs – Part 6: Advice for Emerging Biotechs
  • July 24, 2026
  • 13 min
  1. Emerging biotech companies must develop strategies considering manufacturability, funding, and long-term commercial goals.
  2. Selecting the right CRO/CDMO early is crucial to avoid costly revisions and ensure alignment with company goals.
  3. Building a solid scientific foundation and understanding the market landscape are essential for attracting investment.
  4. Engaging experienced partners early can help mitigate risks and improve resource utilization in drug development.
  5. Successful biotechs focus on reducing risk and providing clear value propositions to attract investors and partners.
...more